Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant

HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss

Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.

Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications

FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.

Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer

Resalis Therapeutics announced the appointment of Dr. Diana M. Røpcke as Chief Medical Officer to lead clinical strategy for RES-010, an antisense oligonucleotide in Phase 1b trials for obesity treatment. Dr. Røpcke brings extensive experience from Novo Nordisk in clinical drug development and cardiometabolic therapies.

FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients

8-K filing — Vivani Medical, Inc. (VANI)

Filed: 2026-08-17 AccNo: 0001753926-26-001536 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from